Q&A with Matthew Sappern, CEO at PeriGen

Media 7 | September 30, 2021

Matthew Sappern, CEO at PeriGen
Matthew Sappern, CEO at PeriGen, had served as a corporate officer for Eclipsys Corporation before and during its merger with Allscripts. Leading up to the merger, Sappern served as Eclipsys Senior Vice President of Professional Services, responsible for the company’s $100M consulting, implementation and training P&L. Sappern joined Eclipsys in January 2003, as VP of product development in the software engineering division. Over a time of three years, he came to run 75 percent of the development operation and oversaw the delivery of three critical enterprise software releases in record time for the company.

We are at the beginning of a remarkable age of technical and clinical alchemy.



MEDIA 7: You have had a profound professional career of over 30 years, could you please share a glimpse of your wonderful journey?
MATTHEW SAPPERN:
My career has been anything but a straight line. I actually started in the media industry and thirty years later I am fortunate to be leading a team of mission-driven healthcare professionals and technologists, making what I believe is a profound difference in the lives of mothers and babies. I have benefitted from proximity to talented, brilliant people just about everywhere I have worked.


M7: What are your thoughts on the penetration of ‘Artificial Intelligence’ in the healthcare domain and what changes do you see happening in the near future?
MS:
AI is still a nascent idea in healthcare, limited by quality data and by clinical acceptance. This will change over time. The sheer number of patients vs healthcare workers present challenges of scale and resultingly open the door to automation of all types. In my experience, I have come to believe that machine learning technologies can and should play a critical part in augmenting, not replacing, current clinical care. These tools can reduce the amount of subjectivity and variability in the assessment and delivery of care and reduce clinical bias and normalization of deviance which have a negative impact on the quality of care.


Machine learning technologies can and should play a critical part in augmenting, not replacing, current clinical care.



M7: PeriGen’s mission is ‘Protect Moms and Babies.’ To what extent has PeriGen’s AI patient safety platform improved the ‘Labor and Delivery’ healthcare?
MS:
PeriGen solutions use AI tools to augment subjective assessments with objective, data-driven assessments. More than half the adverse events in term births are preventable and studies show a prevalence of delayed recognition and response to clinical warning signs. In L&D, a single nurse is typically the arbiter of how a mother or fetus is tolerating labor and that can be dangerous. Variation in experience, training, clinical bias, and normalization of deviance all challenge that nurse as she strives to make the right call, and to effectively communicate her clinical assessments to the rest of the care team. 


M7: Could you please give us an insight about the upcoming ‘@AWHONN Virtual Conference’ and what message does it hold for the attendees?
MS:
I don’t have much insight other than I think everyone was hoping to get together in person, but safety has to come first. I am sure the decision to go virtual was difficult but governed by concern for the nursing constituency.


In short: find smart, committed people and pave their way.



M7: You have led PeriGen through a period of innovation and growth as well as multiplied its market share and revenue. Would you like to share some of your preferred strategies behind this success?
MS:
For the last decade I held fast to the fundamental view that technology should be helping nurses manage in an increasingly challenging clinical environment. I never wavered from this view. I then surrounded myself with brilliant people, made sure they understood and believed in the mission, and did my best to listen and move obstacles to let these brilliant people do their thing. In short: find smart, committed people and pave their way.


M7: What advice would you like to give our readers starting their careers in this sector?
MS:
I believe we are at the beginning of a remarkable age of technical and clinical alchemy, so your timing is perfect. Always maintain a great respect for the healthcare providers you work with because the secret is to design great technology that these amazing people want to use.

ABOUT PERIGEN

PeriGen is the global leader in applying AI to perinatal care. It is the only technology company deploying FDA-cleared AI algorithms at the bedside, its software has been featured in numerous peer-reviewed publications and has been shown to help health systems significantly reduce unanticipated NICU transfers.

More C-Suite on deck

Q&A with Anna Baecklund, CTO & Founder at Oppioo

Media 7 | September 21, 2021

Anna Baecklund, CTO & Founder at Oppioo, is a Data Scientist Leader, A skilled communicator capable of explaining complex issues with clarity to diverse audiences. With MSc in engineering physics, Anna is responsible for leading innovation using data science including the development of new insights, advanced modelling techniques, and AI capabilities. With Oppio, An AI companion app, she aims to motivate cancer patients who want to speed up and improve their rehab.

Read More

Q&A with Bill Gianoukos, CEO at Goodpath

Media 7 | September 14, 2021

Bill Gianoukos, Co-founder and CEO of Goodpath, started Goodpath in 2018 with a mission to improve the ‘Quality Of Life’ for those suffering from chronic conditions. He is also a Mentor at Techstars, and an Investor at Wappier: Intelligent Revenue Management.

Read More

Q&A with Paula Muto, Founder and CEO of UBERDOC Inc.

September 6, 2021

Paula Muto, M.D., F.A.C.S., Founder and CEO of UBERDOC, is also the Director of the Vein Center at Mutosurgical. A graduate of Amherst College and New York Medical College, Dr. Muto is a fellowship-trained vascular surgeon by specialty who also practices general surgery. Paula is an advocate of disruption in healthcare and speaks passionately on many issues regarding transparency in healthcare, patient rights, and ensuring patient access to the care they need and deserve.

Read More

Q&A with Anna Baecklund, CTO & Founder at Oppioo

Media 7 | September 21, 2021

Anna Baecklund, CTO & Founder at Oppioo, is a Data Scientist Leader, A skilled communicator capable of explaining complex issues with clarity to diverse audiences. With MSc in engineering physics, Anna is responsible for leading innovation using data science including the development of new insights, advanced modelling techniques, and AI capabilities. With Oppio, An AI companion app, she aims to motivate cancer patients who want to speed up and improve their rehab.

Read More

Q&A with Bill Gianoukos, CEO at Goodpath

Media 7 | September 14, 2021

Bill Gianoukos, Co-founder and CEO of Goodpath, started Goodpath in 2018 with a mission to improve the ‘Quality Of Life’ for those suffering from chronic conditions. He is also a Mentor at Techstars, and an Investor at Wappier: Intelligent Revenue Management.

Read More

Q&A with Paula Muto, Founder and CEO of UBERDOC Inc.

September 6, 2021

Paula Muto, M.D., F.A.C.S., Founder and CEO of UBERDOC, is also the Director of the Vein Center at Mutosurgical. A graduate of Amherst College and New York Medical College, Dr. Muto is a fellowship-trained vascular surgeon by specialty who also practices general surgery. Paula is an advocate of disruption in healthcare and speaks passionately on many issues regarding transparency in healthcare, patient rights, and ensuring patient access to the care they need and deserve.

Read More

Related News

FUTURE OF HEALTHCARE, DIGITAL HEALTHCARE

MarketVector Indexes™ Licenses the MVIS® Global Bionic Healthcare ESG Index to VanEck Europe

MVIS® Global Bionic Healthcare ESG Index | December 08, 2022

MarketVector IndexesTM announced the licensing of the MVIS® Global Bionic Healthcare ESG Index to underlie the VanEck Bionic Engineering UCITS ETF. The MVIS® Global Bionic Healthcare ESG Index includes companies that generate at least 50% of their revenue from medical, dental, or vision-related implants, bioprinting, prosthesis, or preservation of organs and tissue. “We have observed sound growth in the global bionics market which includes a range of niche healthcare solutions from medical implants to prostheses and bioprinting. These innovations in medical technology open new horizons to meet the rising needs of an aging population, significantly improve the quality of life for people with disabilities, and pave the way for the discovery of potentially life-saving treatments. The MVIS® Global Bionic Healthcare ESG Index offers an investable benchmark to track the leading companies in this industry.” Mirela Stefanova, Manager of Equity Operations at MarketVector The MVIS® Global Bionic Healthcare ESG Index is weighted by free float market capitalization and reviewed on a quarterly basis. The index is calculated in USD as a price index and a total return net index. Capping factors are applied to avoid overweighting of single index components. “The proportion of the elderly population is rising and with it the demand for technical solutions such as hearing and visual aids, pacemakers, artificial joints and the like that improve the quality of life in the old age,” says Martijn Rozemuller, CEO at VanEck Europe. “At the same time, increasingly available bionic tools are helping people with chronic diseases such as diabetes or functional disorders.” About MarketVector Indexes MarketVector IndexesTM is a regulated Benchmark Administrator in Europe, incorporated in Germany and registered with the Federal Financial Supervisory Authority (BaFin). MarketVector maintains indexes under the MarketVectorTM, MVIS® and BlueStar® names. With a mission to accelerate index innovation globally, MarketVector is best known for its broad suite of Thematic indexes, a long-running expertise in Hard Asset-linked Equity indexes, and its pioneering Digital Asset index family. MarketVector is proud to be in partnership with more than 25 Exchange Traded Product issuers and index fund managers in markets throughout the world, with approximately USD 26.99 billion in assets under management.

Read More

FUTURE OF HEALTHCARE, DIGITAL HEALTHCARE

BioNJ Hosts Its Inaugural Health Equity in Clinical Trials MBA Business Plan Case Competition

BioNJ | December 07, 2022

BioNJ, New Jersey's life sciences trade association, hosted an Inaugural Health Equity in Clinical Trials MBA Business Plan Case Competition on Saturday, December 3, at Rutgers Business School. BioNJ's Business Plan Case Competition, which is part of a broader BioNJ strategic initiative of Health Equity in Clinical Trials, was designed to promote the next generation of diverse clinical trial innovators and identify innovative approaches and successful models that can be used nationally to strengthen diversity in clinical trials and expand health equity. BioNJ believes that health equity in clinical trials is critical to deepening the understanding of the safety and efficacy of medicines in under-represented populations, expanding access to medical innovation for these populations and increasing dialogue and trust among the biopharma industry, communities and healthcare systems. By discovering new approaches, utilizing new technologies and developing new business standards to make trials more accessible, we can work to create more agile, efficient and Patient-centered medical research. Eight teams, competing for more than $20,000 in prize money, were tasked with developing a business plan defining a new solution, application or technology to help address this important and challenging problem. Teams identified one particular type of health disparity on which to frame their proposed solutions and connected with community-based organizations to better understand the real-world barriers that exist for their chosen populations to engage in clinical trials. The disease areas on which the respective teams focused included Alzheimer's, heart failure, multiple sclerosis, diabetes type 1 and type 2, colorectal and cervical cancers, and oncology. "There is an urgent need to bring more diversity to clinical trials in order to better serve Patients and their communities…thereby helping to address health inequities. Only by improving diversity in clinical trials will we be able to deepen our understanding of the safety and efficacy of medicines for all populations. I am extremely proud of our teams. Each of the business plans offered a unique out-of-the-box solution – helping advance our ambition to have no Patient left behind." Amadou Diarra, Ph.D., Senior Vice President, Global Policy, Advocacy & Government Affairs for Bristol Myers Squibb; BioNJ Board Member and Chair of the BioNJ Health Equity in Clinical Trials Initiative Live pitch presentations were made throughout the day to a Panel of Judges comprised of industry experts Naikia Atkinson, Director, U.S. Clinical Trials Diversity and Inclusion, Sanofi Schylr Greggs, Director, Technology Operations, Medidata Sharon Hanlon, Head, Clinical Trial Engagement & Enrollment, Bristol Myers Squibb Maribel Hernandez, Vice President, Clinical Operations & Special Projects, PTC Therapeutics Jack Rosenberg, Manager, Investments and Business Development, TrialSpark Del Smith, Co-Founder & CEO, Acclinate Lolita Smith, Program Manager, Rare Disease Diversity Coalition, Black Women's Health Imperative Matt Walz, CEO, TrialBee "Although ultimately three winning teams were presented with cash prizes, each team has made a difference for Patients by offering new solutions and technologies to better serve Patients, build community trust and address gaps in health care delivery," said Paul Howard, Ph.D., BioNJ Business Case Competition Steering Committee Chair and Senior Director, Public Policy for Amicus Therapeutics. "This is just the start as we work to share these proposals more broadly." A white paper with all of the presentations will be published in April and rolled out during BioNJ's acclaimed BioPartnering Conference – which brings together more than 500 industry professionals from around the globe. The three winning teams will present their plans during the April 18 BioPartnering Conference and all of the students are invited to attend to meet the community. About BioNJ BioNJ is the life sciences trade association for New Jersey, representing close to 400 research-based life sciences organizations and stakeholders across the healthcare ecosystem from the largest biopharmaceutical companies to early stage start-ups for nearly 30 years. Because Patients Can't Wait®, BioNJ is dedicated to ensuring a vibrant ecosystem where Science is Supported, Companies are Created, Drugs are Developed and Patients Have Access to Lifesaving Medicines.

Read More

HEALTHTECH SECURITY

Carenet Health Acquires Stericycle Communication Solutions, Creating Industry’s Most Comprehensive Healthcare Consumer Engagement Company

Carenet Health | December 02, 2022

Carenet Health, a leading provider of 24/7 and on-demand patient engagement solutions announced it has acquired Stericycle Communication Solutions, an industry leader in patient engagement technology and solutions and a service of Stericycle, Inc. as part of its strategic vision to create a cohesive patient experience and provide better healthcare for all. The acquisition strengthens Carenet’s robust capabilities in the payer, healthcare services, and clinical arenas by adding provider-centric technology services including online scheduling platforms, automated messaging solutions, and additional inbound and outbound call center services. The combined entity provides 1 in 3 Americans access to Carenet offerings and works with 14 of the top 20 health systems in the U.S., among 1,000 other leading healthcare companies. “At this critical moment in healthcare, where health systems are working hard to get patients back in the door for needed procedures, we’re pleased to be able to provide 24/7 modernized and elevated technology tools with the overall goals of better access, better experiences, better outcomes, and better profitability. Carenet is now the industry’s most experienced and comprehensive healthcare consumer engagement company, delivering dynamic integrated solutions that support the ongoing shift to value-based care.” John Erwin, Carenet chief executive officer In addition to Carenet’s Intelligent Engagement™ clinical and telehealth services, Carenet’s offerings now include Best-in-class Intelligent Scheduling solution, built on the InQuicker™ scheduling platform, that enables patients to convert at the moment of intent Broadest and deepest EHR/EMR integrated solution in the marketplace Award-winning SaaS digital and automation platforms with natural language processing and multi-language capabilities Partnerships with leading health-tech innovators, including leading search platforms Fully API-enabled enterprise platform Carenet’s Matt Dickson, formerly senior vice president at Stericycle Communication Solutions, said the deal is a great fit for both companies. “The acquisition creates an enhanced and powerful end-to-end clinical solution for payers, providers, and healthcare partners that eliminates costly handoffs and multi-vendor management headaches,” Dickson said. “Additionally, our hospital and health system customers will continue to receive the top-notch service they expect while also benefiting from Carenet’s deep clinical expertise and resources. The strategic marriage of tech-enabled communications and expert human capital is a recipe for success during this time of worker shortages, delayed care, and heightened interest in non-traditional venues of healthcare.” Carenet’s enhanced portfolio brings together a human touch to patient engagement and innovative technology solutions to deliver meaningful improvements to patient experience and health outcomes while strengthening provider, payer, and healthcare partner successes. “We’re excited to build on our more than 30 years of expertise by exponentially improving our ability to modernize and optimize the delivery of the healthcare consumer experience across the entire patient engagement journey,” said Mick Mazour, Carenet president. “It’s an essential moment in time for healthcare, and we’re well-positioned to answer the industry’s call for better healthcare for all.” About Carenet Health Carenet Health is the industry's leading healthcare consumer engagement company, providing member and patient engagement, clinical support, virtual care, online scheduling, and advocacy solutions for providers, payers, and partners. One in three Americans have access to Carenet's services. The global company is headquartered in San Antonio, Texas. About Stericycle Communication Solutions Stericycle Communication Solutions is an industry leading provider of patient engagement solutions, providing online scheduling, automated messaging, and strategic inbound and outbound call center services to drive patient access, action, and adherence. Combining a human touch with innovative technologies, Stericycle Communication Solutions delivers a comprehensive patient engagement platform that helps clients acquire and retain patients, achieve higher customer satisfaction rates, enhance their brands, and grow revenue.

Read More

FUTURE OF HEALTHCARE, DIGITAL HEALTHCARE

MarketVector Indexes™ Licenses the MVIS® Global Bionic Healthcare ESG Index to VanEck Europe

MVIS® Global Bionic Healthcare ESG Index | December 08, 2022

MarketVector IndexesTM announced the licensing of the MVIS® Global Bionic Healthcare ESG Index to underlie the VanEck Bionic Engineering UCITS ETF. The MVIS® Global Bionic Healthcare ESG Index includes companies that generate at least 50% of their revenue from medical, dental, or vision-related implants, bioprinting, prosthesis, or preservation of organs and tissue. “We have observed sound growth in the global bionics market which includes a range of niche healthcare solutions from medical implants to prostheses and bioprinting. These innovations in medical technology open new horizons to meet the rising needs of an aging population, significantly improve the quality of life for people with disabilities, and pave the way for the discovery of potentially life-saving treatments. The MVIS® Global Bionic Healthcare ESG Index offers an investable benchmark to track the leading companies in this industry.” Mirela Stefanova, Manager of Equity Operations at MarketVector The MVIS® Global Bionic Healthcare ESG Index is weighted by free float market capitalization and reviewed on a quarterly basis. The index is calculated in USD as a price index and a total return net index. Capping factors are applied to avoid overweighting of single index components. “The proportion of the elderly population is rising and with it the demand for technical solutions such as hearing and visual aids, pacemakers, artificial joints and the like that improve the quality of life in the old age,” says Martijn Rozemuller, CEO at VanEck Europe. “At the same time, increasingly available bionic tools are helping people with chronic diseases such as diabetes or functional disorders.” About MarketVector Indexes MarketVector IndexesTM is a regulated Benchmark Administrator in Europe, incorporated in Germany and registered with the Federal Financial Supervisory Authority (BaFin). MarketVector maintains indexes under the MarketVectorTM, MVIS® and BlueStar® names. With a mission to accelerate index innovation globally, MarketVector is best known for its broad suite of Thematic indexes, a long-running expertise in Hard Asset-linked Equity indexes, and its pioneering Digital Asset index family. MarketVector is proud to be in partnership with more than 25 Exchange Traded Product issuers and index fund managers in markets throughout the world, with approximately USD 26.99 billion in assets under management.

Read More

FUTURE OF HEALTHCARE, DIGITAL HEALTHCARE

BioNJ Hosts Its Inaugural Health Equity in Clinical Trials MBA Business Plan Case Competition

BioNJ | December 07, 2022

BioNJ, New Jersey's life sciences trade association, hosted an Inaugural Health Equity in Clinical Trials MBA Business Plan Case Competition on Saturday, December 3, at Rutgers Business School. BioNJ's Business Plan Case Competition, which is part of a broader BioNJ strategic initiative of Health Equity in Clinical Trials, was designed to promote the next generation of diverse clinical trial innovators and identify innovative approaches and successful models that can be used nationally to strengthen diversity in clinical trials and expand health equity. BioNJ believes that health equity in clinical trials is critical to deepening the understanding of the safety and efficacy of medicines in under-represented populations, expanding access to medical innovation for these populations and increasing dialogue and trust among the biopharma industry, communities and healthcare systems. By discovering new approaches, utilizing new technologies and developing new business standards to make trials more accessible, we can work to create more agile, efficient and Patient-centered medical research. Eight teams, competing for more than $20,000 in prize money, were tasked with developing a business plan defining a new solution, application or technology to help address this important and challenging problem. Teams identified one particular type of health disparity on which to frame their proposed solutions and connected with community-based organizations to better understand the real-world barriers that exist for their chosen populations to engage in clinical trials. The disease areas on which the respective teams focused included Alzheimer's, heart failure, multiple sclerosis, diabetes type 1 and type 2, colorectal and cervical cancers, and oncology. "There is an urgent need to bring more diversity to clinical trials in order to better serve Patients and their communities…thereby helping to address health inequities. Only by improving diversity in clinical trials will we be able to deepen our understanding of the safety and efficacy of medicines for all populations. I am extremely proud of our teams. Each of the business plans offered a unique out-of-the-box solution – helping advance our ambition to have no Patient left behind." Amadou Diarra, Ph.D., Senior Vice President, Global Policy, Advocacy & Government Affairs for Bristol Myers Squibb; BioNJ Board Member and Chair of the BioNJ Health Equity in Clinical Trials Initiative Live pitch presentations were made throughout the day to a Panel of Judges comprised of industry experts Naikia Atkinson, Director, U.S. Clinical Trials Diversity and Inclusion, Sanofi Schylr Greggs, Director, Technology Operations, Medidata Sharon Hanlon, Head, Clinical Trial Engagement & Enrollment, Bristol Myers Squibb Maribel Hernandez, Vice President, Clinical Operations & Special Projects, PTC Therapeutics Jack Rosenberg, Manager, Investments and Business Development, TrialSpark Del Smith, Co-Founder & CEO, Acclinate Lolita Smith, Program Manager, Rare Disease Diversity Coalition, Black Women's Health Imperative Matt Walz, CEO, TrialBee "Although ultimately three winning teams were presented with cash prizes, each team has made a difference for Patients by offering new solutions and technologies to better serve Patients, build community trust and address gaps in health care delivery," said Paul Howard, Ph.D., BioNJ Business Case Competition Steering Committee Chair and Senior Director, Public Policy for Amicus Therapeutics. "This is just the start as we work to share these proposals more broadly." A white paper with all of the presentations will be published in April and rolled out during BioNJ's acclaimed BioPartnering Conference – which brings together more than 500 industry professionals from around the globe. The three winning teams will present their plans during the April 18 BioPartnering Conference and all of the students are invited to attend to meet the community. About BioNJ BioNJ is the life sciences trade association for New Jersey, representing close to 400 research-based life sciences organizations and stakeholders across the healthcare ecosystem from the largest biopharmaceutical companies to early stage start-ups for nearly 30 years. Because Patients Can't Wait®, BioNJ is dedicated to ensuring a vibrant ecosystem where Science is Supported, Companies are Created, Drugs are Developed and Patients Have Access to Lifesaving Medicines.

Read More

HEALTHTECH SECURITY

Carenet Health Acquires Stericycle Communication Solutions, Creating Industry’s Most Comprehensive Healthcare Consumer Engagement Company

Carenet Health | December 02, 2022

Carenet Health, a leading provider of 24/7 and on-demand patient engagement solutions announced it has acquired Stericycle Communication Solutions, an industry leader in patient engagement technology and solutions and a service of Stericycle, Inc. as part of its strategic vision to create a cohesive patient experience and provide better healthcare for all. The acquisition strengthens Carenet’s robust capabilities in the payer, healthcare services, and clinical arenas by adding provider-centric technology services including online scheduling platforms, automated messaging solutions, and additional inbound and outbound call center services. The combined entity provides 1 in 3 Americans access to Carenet offerings and works with 14 of the top 20 health systems in the U.S., among 1,000 other leading healthcare companies. “At this critical moment in healthcare, where health systems are working hard to get patients back in the door for needed procedures, we’re pleased to be able to provide 24/7 modernized and elevated technology tools with the overall goals of better access, better experiences, better outcomes, and better profitability. Carenet is now the industry’s most experienced and comprehensive healthcare consumer engagement company, delivering dynamic integrated solutions that support the ongoing shift to value-based care.” John Erwin, Carenet chief executive officer In addition to Carenet’s Intelligent Engagement™ clinical and telehealth services, Carenet’s offerings now include Best-in-class Intelligent Scheduling solution, built on the InQuicker™ scheduling platform, that enables patients to convert at the moment of intent Broadest and deepest EHR/EMR integrated solution in the marketplace Award-winning SaaS digital and automation platforms with natural language processing and multi-language capabilities Partnerships with leading health-tech innovators, including leading search platforms Fully API-enabled enterprise platform Carenet’s Matt Dickson, formerly senior vice president at Stericycle Communication Solutions, said the deal is a great fit for both companies. “The acquisition creates an enhanced and powerful end-to-end clinical solution for payers, providers, and healthcare partners that eliminates costly handoffs and multi-vendor management headaches,” Dickson said. “Additionally, our hospital and health system customers will continue to receive the top-notch service they expect while also benefiting from Carenet’s deep clinical expertise and resources. The strategic marriage of tech-enabled communications and expert human capital is a recipe for success during this time of worker shortages, delayed care, and heightened interest in non-traditional venues of healthcare.” Carenet’s enhanced portfolio brings together a human touch to patient engagement and innovative technology solutions to deliver meaningful improvements to patient experience and health outcomes while strengthening provider, payer, and healthcare partner successes. “We’re excited to build on our more than 30 years of expertise by exponentially improving our ability to modernize and optimize the delivery of the healthcare consumer experience across the entire patient engagement journey,” said Mick Mazour, Carenet president. “It’s an essential moment in time for healthcare, and we’re well-positioned to answer the industry’s call for better healthcare for all.” About Carenet Health Carenet Health is the industry's leading healthcare consumer engagement company, providing member and patient engagement, clinical support, virtual care, online scheduling, and advocacy solutions for providers, payers, and partners. One in three Americans have access to Carenet's services. The global company is headquartered in San Antonio, Texas. About Stericycle Communication Solutions Stericycle Communication Solutions is an industry leading provider of patient engagement solutions, providing online scheduling, automated messaging, and strategic inbound and outbound call center services to drive patient access, action, and adherence. Combining a human touch with innovative technologies, Stericycle Communication Solutions delivers a comprehensive patient engagement platform that helps clients acquire and retain patients, achieve higher customer satisfaction rates, enhance their brands, and grow revenue.

Read More

Spotlight

PeriGen

PeriGen

PeriGen is the global leader in applying AI to perinatal care. It is the only technology company deploying FDA-cleared AI algorithms at the bedside, its software has been featured in numerous peer-reviewed publications and has been shown to help health systems significantly reduce unanticipated NIC...

Events

Resources

resource image

HEALTH TECHNOLOGY, FUTURE OF HEALTHCARE, HEALTHCARE ANALYTICS

Capgemini World Life and Health Insurance Report 2022

Video

resource image

FUTURE OF HEALTHCARE, DIGITAL HEALTHCARE

What are some the key trends in Healthcare Informatics in 2023?

Video

resource image

HEALTH TECHNOLOGY, DIGITAL HEALTHCARE, MEDICAL DEVICES

Role of AI and ML in the Healthcare Industry

Article

resource image

HEALTH TECHNOLOGY, FUTURE OF HEALTHCARE, HEALTHCARE ANALYTICS

Capgemini World Life and Health Insurance Report 2022

Video

resource image

FUTURE OF HEALTHCARE, DIGITAL HEALTHCARE

What are some the key trends in Healthcare Informatics in 2023?

Video

resource image

HEALTH TECHNOLOGY, DIGITAL HEALTHCARE, MEDICAL DEVICES

Role of AI and ML in the Healthcare Industry

Article

Events